Boston Scientific Corporation
) announced CE Mark approval and the launch of its INGEVITY
family of magnetic resonance imaging (MRI) compatible pacing
leads in Europe. Post announcement, the company's shares rose by
1.5% to close at $13.21 as on Mar 18, 2014.
Boston Scientific's INGEVITY MRI pacing leads belong to the
ImageReady MR-conditional pacemaker system that includes VITALIO
MRI, FORMIO MRI, ADVANTIO MRI and INGENIO MRI pulse generators.
INGEVITY MRI is capable of wirelessly monitoring patients
suffering from conditions like atrial arrhythmias, when used in
conjunction with the LATITUDE NXT patient management system.
Pacing leads are insulated wires that connect the pacemaker to
the heart and stimulate it to restore normal rhythm among people
suffering from bradycardia (slow heartbeat). Boston Scientific's
INGEVITY family offers an all-inclusive set of leads that can be
placed using a 6 French introducer, including passive and active
The INGEVITY pacing lead platform is designed to provide key
enhancements in handling and is specifically engineered to
function in the MRI environment. The subset of data from the
INGEVITY trial supports CE mark approval and showcases
exceptional performance including positive ratings on lead
handling and maneuverability from 99.5% of implanters.
The first implant of the INGEVITY MRI lead was performed on
Mar 3 in Nantes, France. The product proved itself to be highly
The INGEVITY MRI pacing leads are a part of Boston
Scientific's Cardiac Rhythm Management segment which accounted
for 26.4% of total revenues in 2013. Boston Scientific provides a
comprehensive range of leads like RELIANCE 4-FRONT defibrillation
leads, and the ACUITY X4 CRT family of leads along with INGEVITY
MRI pacing leads.
INGEVITY MRI, RELIANCE 4-FRONT, ACUITY X4, and AUTOGEN X4
CRT-D are not yet available for sale in the U.S.
Boston Scientific's ImageReady pacing system is also under
clinical investigation and is still not commercially available in
the U.S. The system, once available, will enable cardiac patients
to undergo MRI scans. On the other hand,
) has already launched its SureScan pacing systems in the U.S.
for full body MRI scans without positioning restrictions.
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth a look in the broader healthcare
). Enzymotec sports a Zacks Rank #1 (Strong Buy) while Covidien
holds a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
ENZYMOTEC LTD (ENZY): Free Stock Analysis
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.